证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，公司始终密切关注汇率走势，积极 运用外汇衍生品等工具，并结合优化结算货币、合理规划外币收支等方式，对冲汇率波动风险，降低汇 兑损益。 （编辑 丛可心） ...

（编辑 丛可心） 证券日报网讯 1月15日，健康元在互动平台回答投资者提问时表示，新元素药业上市尚处于流程推进阶 段，后续进展及潜在价值受市场环境、行业趋势等多重因素影响，存在不确定性，暂无法准确预估。公 司始终秉持长期主义投资理念，聚焦核心战略精选优质标的，新元素药业是公司产业链相关投资的布局 之一。未来，公司将继续砥砺前行，审慎推进各项投资与经营工作，持续为股东创造长期价值。 ...

格隆汇1月15日丨健康元(600380.SH)在投资者互动平台表示，公司在 AI 赋能医药创新领域已迈出坚实 步伐，与腾讯量子实验室的合作取得阶段性成果，双方联合开发的基于深度学习的生物合成基因簇预测 算法架构，相关研究论文已正式发布并共同申请国家发明专利，为 AI 技术在原料药研发、合成生物学 等核心业务场景的落地提供了重要技术支撑。未来，公司将持续加大 AI 技术的研发投入与应用探索力 度，聚焦 AI 在药物分子设计、靶点发现、工艺优化、生产效率提升等关键环节的深度融合，积极挖掘 前沿技术与核心业务的协同价值，全力推动医药研发与产业运营的智能化升级。关于与英伟达的业务往 来，公司目前暂无相关合作及计划，后续若有符合公司战略的合作机会，将积极评估推进。请投资者以 公司公告及官方信息为准，注意投资风险，理性投资。 ...

Group 1 - Health元's stock price increased by 0.99% to 12.21 yuan per share, with a total market capitalization of 22.338 billion yuan and a trading volume of 3.79 billion yuan, marking a cumulative increase of 5.71% over the past seven days [1] - The company, founded on December 18, 1992, and listed on June 8, 2001, operates as a comprehensive pharmaceutical enterprise engaged in the research, development, and production of traditional Chinese medicine, health products, and Western medicine [1] - The main business revenue composition includes: chemical preparations 47.71%, chemical raw materials and intermediates 31.97%, traditional Chinese medicine preparations 10.28%, diagnostic reagents and equipment 4.74%, health food 3.08%, biological products 1.20%, and others 0.86% [1] Group 2 - Longxin Fund has one fund heavily invested in Health元, with Longxin Medical Health Mixed (LOF) A (163001) reducing its holdings by 57,600 shares in the third quarter, now holding 236,000 shares, representing 2.18% of the fund's net value [2] - The fund has generated a floating profit of approximately 28,300 yuan today and a total of 155,800 yuan during the seven-day increase [2] - Longxin Medical Health Mixed (LOF) A (163001) was established on March 26, 2010, with a current scale of 128 million yuan, yielding 8.03% this year and 33.13% over the past year [2]

Core Viewpoint - Health元's subsidiary, Zhuhai Lizhu Biotech Co., Ltd., has announced that its product, Lakanqita monoclonal injection, has been included in the priority review and approval process as of December 26, 2025, marking its entry into the priority review stage for drug marketing authorization [1] Group 1 - The drug is intended for adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy [1] - Lakanqita monoclonal injection is the first domestically developed and the second globally in progress IL-17A/F dual-target inhibitor [1] - The clinical trial, which was multi-center, randomized, double-blind, and positive-controlled, was completed in July 2025, showing that the drug is more effective than the comparator, Secukinumab, with good safety [1] Group 2 - Although the drug application has been accepted, it still requires evaluation and on-site inspection, leaving uncertainty regarding the final approval and market launch timing [1]

Group 1 - Health元药业's subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., has received priority review status for its drug, Laikangqita Monoclonal Antibody Injection, which is intended for adult patients with moderate to severe plaque psoriasis [1][2] - The drug is the first domestically developed and the second globally IL-17A/F dual-target inhibitor, showing superior efficacy in clinical trials compared to the control group [3] - The drug's application for marketing authorization was accepted in December 2025, indicating progress towards potential market entry [4] Group 2 - The priority review was granted based on compliance with the relevant regulations and guidelines set by the National Medical Products Administration [2] - Clinical trials demonstrated that Laikangqita Injection achieved primary and secondary efficacy endpoints, with faster onset and better long-term efficacy compared to the control [3] - The safety profile of the drug was comparable to that of the control group, indicating a favorable risk-benefit ratio [3] Group 3 - Health元药业 has announced a change in the audit project partner for its 2025 financial report, appointing Tang Hanlin as the new project partner due to the previous partner's work adjustment [8][9] - The change in audit personnel is not expected to impact the financial reporting and internal control audit for 2025 [12] Group 4 - In December 2025, Health元药业 provided a guarantee of RMB 120 million for its subsidiary, Lizhu Pharmaceutical Group, to support its operational needs [15] - The company has a total guarantee balance of RMB 2,111.52 million as of December 31, 2025, with no overdue guarantees reported [19][20]

证券日报网讯1月7日，健康元（600380）发布公告称，截至2025年12月31日，公司及控股子公司无对外 担保逾期的情况。 ...

智通财经APP讯，健康元(600380.SH)发布公告，公司控股子公司珠海市丽珠单抗生物技术有限公司(简 称：丽珠单抗)的产品莱康奇塔单抗注射液于2025年12月26日被国家药品监督管理局药品审评中心纳入 拟优先审评品种公示名单;现公示期满后，根据国家药品监督管理局药品审评中心网站信息公开显示， 已纳入优先审评品种名单，正式进入药品上市许可优先审评审批程序。 拟定适应症(或功能主治)：本品用于适合接受系统治疗或光疗的中重度斑块状银屑病成人患者。 ...

关于变更审计项目合伙人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健康元药业集团股份有限公司（以下简称：本公司）于 2025 年 4 月 7 日召开 九届董事会八次会议，审议并通过《关于续聘致同会计师事务所（特殊普通合伙） 为 2025 年度年审会计师事务所的议案》，同意聘用致同会计师事务所（特殊普通 合伙）（以下简称：致同会计师事务所）对公司 2025 年财务报告和内部控制进行 审计并出具审计报告。该议案已经公司 2025 年 6 月 6 日召开的 2024 年度股东大会 审议通过，详见《健康元药业集团股份有限公司关于续聘会计师事务所的公告》（临 2025-027）及《健康元药业集团股份有限公司 2024 年年度股东大会决议公告》（临 2025-048）。 近日，公司收到致同会计师事务所出具的《关于变更公司 2025 年年审项目合 伙人的告知函》，现将具体情况公告如下： 一、本次项目合伙人及签字注册会计师变更的基本情况 健康元药业集团 变更审计项目合伙人的公告 证券代码：600380 证券简称：健康元 公告编号： ...

证券代码：600380 证券简称：健康元 公告编号：临 2026-001 健康元药业集团 担保进展公告 健康元药业集团股份有限公司 关于为控股子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 被担保人名称 | 本次担保金额 | 实际为其提供的担 保余额（不含本次担 保金额） | | 是否在前期预计额 度内 | 本次担保是否有反 担保 | | --- | --- | --- | --- | --- | --- | | 丽珠集团丽珠制药厂 | 万元 12,000.00 | | 万元 23,382.00 | 是 | 否 | | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股子公 司对外担保余额（万元） | 211,151.52 | | 对外担保余额占上市公司最近一期经 | | | 审计净资产的比例（%） | 14.53 | | 净资产 | □担保金额（含本次）超过上市公司最近一期经审计 50% □对外担保总额（含本次）超过 ...